{"@context":"https://schema.org","@type":"Legislation","name":"Reduced Costs and Continued Cures Act of 2021","description":"

Reduced Costs and Continued Cures Act of 2021

This bill establishes and alters several programs and requirements relating to the prices of prescription drugs.

For example, the bill establishes and alters several requirements under Medicare and Medicaid, including

requiring drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services for covered drugs under Medicare that cost $100 or more and for which the average manufacturer price increases faster than inflation,
capping annual out-of-pocket spending under the Medicare prescription drug benefit, and
increasing the maximum rebate amount under the Medicaid Drug Rebate Program.

The bill also makes changes relating to market exclusivities and manufacturer price concessions for prescription drugs, including

authorizing the Federal Trade Commission to initiate proceedings against parties to settlements of patent infringement claims that have anticompetitive effects with respect to drugs or biologics,
limiting in certain instances the number of patents that the manufacturer of a biologic can assert in a lawsuit against a company seeking to sell a biosimilar version, and
nullifying regulations relating to the treatment of certain Medicare prescription drug benefit rebates from drug manufacturers for purposes of federal anti-kickback laws.

","legislationIdentifier":"HR 5237","legislationType":"Bill","legislationLegalForce":"NotInForce","legislationJurisdiction":"USA","author":[{"@type":"Person","name":"Scott H. Peters","url":"https://legisdaily.com/mp/scotth-peters-us"}],"about":{"@type":"Thing","name":"Health"},"keywords":"Accounting and auditing, Administrative law and regulatory procedures, Administrative remedies, Appropriations, Civil actions and liability, Competition and antitrust, Congressional oversight, Consumer affairs, Contracts and agency, Department of Health and Human Services, Digestive and metabolic diseases, Drug safety, medical device, and laboratory regulation, Drug therapy, Federal Trade Commission (FTC), Genetics, Government studies and investigations, Health care costs and insurance, Health care coverage and access, Health care quality, Health programs administration and funding, Health technology, devices, supplies, Home and outpatient care, Inflation and prices, Intellectual property, Intergovernmental relations, Judicial review and appeals, Licensing and registrations, Manufacturing, Marketing and advertising, Medicaid, Medicare, Performance measurement, Prescription drugs, Public contracts and procurement, State and local government operations","dateModified":"2025-01-16T00:00:00.000Z","url":"https://legisdaily.com/bill/USA-117-HR-5237"}